Related Experiment Video

Updated: Aug 13, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

Panagiotis A Konstantinopoulos1, Gerasimos P Vandoros, Athanasios G Papavassiliou

  • 1Department of Biological Chemistry, Medical School, University of Athens, Athens, and Department of Pathology, Aeghion General Hospital, Greece.

Cancer Chemotherapy and Pharmacology
|January 26, 2006
PubMed
Abstract

Insights

FK228, a novel anticancer agent, inhibits histone deacetylases (HDACs) to target cancer. It shows promise by inducing cell death and inhibiting tumor growth and blood vessel formation.

Area of Science:

  • Oncology
  • Epigenetics
  • Pharmacology

Background:

  • Epigenetic alterations are crucial in cancer development.
  • Aberrant histone deacetylase (HDAC) activity promotes tumorigenesis by silencing tumor suppressor genes.
  • Epigenetic targeting represents a novel therapeutic strategy in oncology.

Purpose of the Study:

  • To evaluate the anticancer potential of FK228 (depsipeptide).
  • To investigate the mechanisms underlying FK228's antitumor activity, focusing on HDAC inhibition.

Main Methods:

  • The study focuses on the known properties and effects of FK228.
  • Analysis of gene expression changes induced by FK228.
  • Assessment of FK228's impact on cellular processes like apoptosis and angiogenesis.

Main Results:

  • FK228 treatment upregulates genes associated with cell growth inhibition.
  • FK228 promotes cell differentiation and induces apoptotic cell death.
  • FK228 demonstrates anti-angiogenic properties.

Conclusions:

  • FK228 exhibits multitargeting capabilities, including non-histone targets.
  • The drug displays significant clinical activity with a manageable side-effect profile.
  • FK228 is a highly promising novel therapeutic agent for cancer treatment.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...